Real-World study confirms tildrakizumab controls psoriasis for up to two years
NCT ID NCT04203693
First seen Mar 04, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This observational study followed 331 adults with moderate to severe plaque psoriasis who were treated with tildrakizumab (Ilumetri) in routine medical practice. Researchers measured how much the skin cleared up and how quality of life improved over 48 to 100 weeks. The goal was to see if the drug works as well in real life as it did in earlier clinical trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Investigational Site 1
Nice, France
-
Investigational Site 1
Augsburg, Germany
-
Investigational Site 1
Arezzo, Italy
-
Investigational Site 10
Cologne, Germany
-
Investigational Site 10
Roma, Italy
-
Investigational Site 11
Lübeck, Germany
-
Investigational Site 11
Roma, Italy
-
Investigational Site 12
München, Germany
-
Investigational Site 12
Rozzano, Italy
-
Investigational Site 13
Merzig, Germany
-
Investigational Site 14
Oberursel, Germany
-
Investigational Site 15
Quedlinburg, Germany
-
Investigational Site 2
Berlin, Germany
-
Investigational Site 2
Brescia, Italy
-
Investigational Site 3
Bochum, Germany
-
Investigational Site 3
Catania, Italy
-
Investigational Site 4
Erlangen, Germany
-
Investigational Site 4
Florence, Italy
-
Investigational Site 5
Greifswald, Germany
-
Investigational Site 5
Genova, Italy
-
Investigational Site 6
Hamburg, Germany
-
Investigational Site 6
Lecce, Italy
-
Investigational Site 7
Halle, Germany
-
Investigational Site 7
Modena, Italy
-
Investigational Site 8
Kiel, Germany
-
Investigational Site 8
Roma, Italy
-
Investigational Site 9
Kiel, Germany
-
Investigational Site 9
Roma, Italy
-
Investigational site 1
Breda, Netherlands
-
Investigator Site 1
Baden, Austria
-
Investigator Site 1
Brussels, Belgium
-
Investigator Site 2
Vienna, Austria
-
Investigator Site 2
Charleroi, Belgium
-
Investigator Site 2
Poitiers, France
-
Investigator Site 3
Genk, Belgium
-
Investigator Site 4
Ghent, Belgium
-
Investigator Site 5
Herstal, Belgium
-
Investigator Site 6
Jette, Belgium
-
Investigator Site 7
Lede, Belgium
-
Investigator Site 8
Leuven, Belgium
-
Investigator Site 9
Mons, Belgium
Conditions
Explore the condition pages connected to this study.